Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.
Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.